Abstract

MOLECULAR TARGETS OF METFORMIN IN TRIPLE NEGATIVE BREAST CANCER: A REVIEW

Ayushi* and Avantika Jain

.

Abstract

Triple negative breast cancers are the type of breast cancers which are negative for expression of the steroid receptors estrogen and progesterone as well as tyrosine kinase receptor HER-2. Since TNBC is an aggressive cancer and has shortage of specific therapeutic options, there is a need to peruse the ways in which TNBC develops and how it can be treated by using specific molecular targets. Extremely low glucose concentration and calorie restriction have shown to enhance the anti-tumorigenic effect of cancer. Metformin is being used for a very long time for the treatment of type-2 diabetes mellitus and its therapeutic effects include the maintenance of normal blood glucose levels. Therefore, in the current report, we will try to compile and explore the possible mechanism of metformin’s anticancer profile against TNBC with thorough crosstalk among the existing research conducted in metformin in both preclinical and clinical settings.

Keywords: Triple negative breast cancer, metformin, molecular targets, clinical trials, preclinical trials.